Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
出版年份 2023 全文链接
标题
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
作者
关键词
-
出版物
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-03
DOI
10.1007/s10928-023-09884-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of and insights from systems pharmacology models of antibody‐drug conjugates
- (2022) Inez Lam et al. CPT-Pharmacometrics & Systems Pharmacology
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)
- (2022) Kevin Beaumont et al. XENOBIOTICA
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
- (2021) Kohei Shitara et al. Gastric Cancer
- Antibody‒drug conjugates: Recent advances in linker chemistry
- (2021) Zheng Su et al. Acta Pharmaceutica Sinica B
- Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
- (2021) Gail Lewis Phillips et al. BREAST CANCER RESEARCH AND TREATMENT
- An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens
- (2020) Bruna Menezes et al. AAPS Journal
- Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
- (2020) Hiromi Okamoto et al. XENOBIOTICA
- Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
- (2020) Alison Betts et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach
- (2019) Katherine Kay et al. AAPS Journal
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach
- (2018) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)
- (2016) Aman P. Singh et al. AAPS Journal
- Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
- (2016) Alison M. Betts et al. AAPS Journal
- Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design
- (2016) Katie F. Maass et al. AAPS Journal
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Quantitative Systems Pharmacology: A Case for Disease Models
- (2016) CJ Musante et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography
- (2016) Su Hyun Lee et al. MEDICINE
- SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
- (2015) K. J. Hamblett et al. CANCER RESEARCH
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
- (2015) Christina Vasalou et al. PLoS One
- High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction
- (2015) Victor S. Goldmacher et al. PLoS One
- A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate
- (2014) Dhaval K. Shah et al. AAPS Journal
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
- (2013) Matthew D. Onsum et al. AMERICAN JOURNAL OF PATHOLOGY
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
- (2013) Nahor Haddish-Berhane et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
- (2013) YORIKO YAMASHITA-KASHIMA et al. ONCOLOGY REPORTS
- A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
- (2012) Brendan C. Bender et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
- (2012) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Human Tumor Xenografts: The Good, the Bad, and the Ugly
- (2012) Richard A Morgan MOLECULAR THERAPY
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
- (2011) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
- (2010) Nelson L. Jumbe et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A practical guide to understanding Kaplan-Meier curves
- (2010) Jason T. Rich et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
- (2008) Suhail M. Ali et al. CANCER
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- (2008) Simeone Marino et al. JOURNAL OF THEORETICAL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now